0001209191-20-063449.txt : 20201215
0001209191-20-063449.hdr.sgml : 20201215
20201215160117
ACCESSION NUMBER: 0001209191-20-063449
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201214
FILED AS OF DATE: 20201215
DATE AS OF CHANGE: 20201215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Valamehr Bahram
CENTRAL INDEX KEY: 0001748177
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 201389575
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, STE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3535 GENERAL ATOMICS COURT
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 3535 GENERAL ATOMICS COURT
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-14
0
0001434316
FATE THERAPEUTICS INC
FATE
0001748177
Valamehr Bahram
C/O FATE THERAPEUTICS, INC.
3535 GENERAL ATOMICS COURT, SUITE 200
SAN DIEGO
CA
92121
0
1
0
0
Chief Development Officer
Common stock
2020-12-14
4
M
0
25000
2.90
A
112211
D
Common stock
2020-12-14
4
S
0
1813
95.8947
D
110398
D
Common stock
2020-12-14
4
S
0
11765
96.6546
D
98633
D
Common stock
2020-12-14
4
S
0
2946
97.6959
D
95687
D
Common stock
2020-12-14
4
S
0
3148
98.7969
D
92539
D
Common stock
2020-12-14
4
S
0
3822
99.7685
D
88717
D
Common stock
2020-12-14
4
S
0
400
100.97
D
88317
D
Common stock
2020-12-14
4
S
0
1006
102.063
D
87311
D
Common stock
2020-12-14
4
S
0
100
102.75
D
87211
D
Stock Option (right to buy)
2.90
2020-12-14
4
M
0
25000
D
2026-01-07
Common Stock
25000
41156
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.
Represents the weighted average sale price of shares sold ranging from $95.23 to $96.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of shares sold ranging from $96.23 to $97.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of shares sold ranging from $97.27 to $98.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of shares sold ranging from $98.28 to $99.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of shares sold ranging from $99.28 to $100.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of shares sold ranging from $100.48 to $101.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of shares sold ranging from $101.56 to $102.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
This option is fully vested.
Not applicable.
/s/ Cindy R. Tahl, as Attorney-in-Fact
2020-12-15